Yi Li Ha Sa Ke Zi Zhi Zhou

Researchers are investigating acute aortic syndrome AAS, a serious and life-threatening heart condition where inflammation plays a significant role in its development and progression. This large observational study involves 20 cardiovascular centers in China collaborating to understand inflammatory responses and anti-inflammatory treatments in patients undergoing surgery for AAS. The study aims to assess how inflammation and anti-inflammatory strategies affect patient outcomes after surgery, including complications and survival. The study enrolls adult patients who have undergone surgery for AAS, which includes various types of aortic injuries such as dissection, penetrating ulcers, or hematomas. Participants may have received medical therapy, open surgery, endovascular repair, or hybrid procedures, sometimes combined with other cardiac surgeries. Data about their inflammatory responses and clinical results are collected through designed forms and analyzed using statistical software. This observational study began in 2016 and will continue enrolling patients until 2040. Participants will be followed over time to evaluate key outcomes like severe inflammatory reactions within 7 days after surgery and operative mortality within 30 days. Researchers will also monitor other complications such as organ dysfunction, stroke, kidney injury, infections, bleeding, and length of intensive care stay. The study gathers detailed information through clinical data collection and monitors these outcomes to better understand and improve management for patients with AAS over the long term.

Primary aldosteronism PA is a common cause of secondary hypertension, and its diagnosis and treatment pose significant challenges. This research investigates adrenal venous sampling AVS, which is considered the best method to distinguish between different types of PA. The study aims to address clinical, technical, and methodological questions about AVS and to understand how AVS-guided management influences long-term health and biochemical results to improve patient care. Participants with PA will undergo adrenal venous sampling through either the antecubital or femoral vein to identify whether aldosterone overproduction is unilateral or bilateral. This observational study evaluates the AVS procedure itself and its clinical outcomes, refining protocols and standardizing practices to optimize treatment decisions and patient prognosis. Throughout the study, researchers will monitor major cardiovascular events one year after AVS. They will also assess procedure success rates, complications, medication changes, blood pressure, heart and kidney function, and clinical outcomes over multiple years. The follow-up includes assessments at 1, 3, 6, 12, 18 months, and up to 10 years, enabling comprehensive evaluation of long-term effects and safety.

Systemic inflammatory response syndrome SIRS and multiple organ dysfunction syndrome MODS are major causes of death in patients with acute aortic syndrome AAS. Researchers are evaluating whether immunomodulatory therapy with thymosin alpha 1 during the acute phase of AAS can reduce the incidence of SIRS and MODS. This study is designed to test this hypothesis in patients undergoing emergency surgery for acute aortic syndrome. Participants will be randomly assigned to receive either thymosin alpha 1 or no additional treatment blank control. Thymosin alpha 1 is given as a 1.6 mg injection under the skin every 12 hours for 5 days during ICU admission. The treatment will stop if the patient is discharged from the ICU or dies. This randomized study uses triple masking to compare the effects of thymosin alpha 1 versus no treatment. During the study, researchers will monitor patients for 7 days after surgery, focusing on the highest Sequential Organ Failure Assessment SOFA score as the main outcome. They will also track 30-day mortality after randomization. Participants will be closely observed in the ICU while receiving treatment, and their organ function and immune response will be assessed. The study lasts through the critical postoperative period to evaluate safety and health outcomes related to thymosin alpha 1 administration.

Researchers are evaluating the effect of ShengXian-QuYu Decoction on quality of life, symptoms, and biomarkers in patients with heart failure who have reduced or mildly reduced ejection fraction. This is a nationwide, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to assess this traditional Chinese medicine compared to a placebo alongside standard care. The trial will also analyze results within subgroups based on factors like heart failure characteristics, comorbidities, and baseline biomarkers. Participants will be randomly assigned to receive either the ShengXian-QuYu Decoction or a placebo, both given orally twice daily. The decoction contains specific herbal ingredients including Astragalus membranaceus and Panax ginseng, among others. The study treatment is added to each patients usual care, and the effects will be monitored over a 12-week period, with some measures extending up to 26 weeks. During the study, participants will undergo various assessments including quality of life questionnaires, symptom scoring based on Traditional Chinese Medicine standards, exercise capacity tests, and measurement of heart function and kidney filtration. Biomarkers such as N-terminal pro-brain natriuretic peptide will also be tracked. Safety and adherence will be monitored throughout the study, which started in March 2023 and is expected to complete by the end of 2025.